A Mason-based early-stage biopharma startup that’s developing a new pipeline of drugs to treat musculoskeletal disorders like osteoarthritis closed a $4 million seed round earlier this month, marking a significant stepping stone for the company, officials said.
Amplicore Inc., founded in 2018 by University of Cincinnati scientist Chia-Ying “James” Lin, will use the funds to complete preclinical development of its two leading products, AM3101 and AM1101, or treatments for meniscus tears and osteoarthritis, respectfully.
Click here to read the complete story.
Story excerpt provided by Cincy Inno.
Written by Liz Engel.
Originally published March 19, 2021.